Agenus Appoints Ulf Wiinberg to Board of Directors
May 19 2016 - 8:50AM
Business Wire
-Serves on boards of Avillion, Hansa Medical,
Nestle Health Science, UCB SA -
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company
developing antibodies including checkpoint inhibitors and other
checkpoint modulators, and cancer vaccines, today announced the
appointment of Ulf Wiinberg to the Company’s Board of Directors.
Ulf has more than 30 years of pharmaceutical experience and
currently serves on the boards of multiple global drug development
companies.
“Ulf’s extensive industry experience in leadership roles, along
with his unique perspective and insight of the global
biopharmaceutical industry, will be invaluable as we advance our
pipeline of immuno-oncology product candidates, including
antibodies and vaccines, through clinical development, partnership
activities and commercialization,” said Garo H. Armen, Ph.D.,
Chairman and CEO of Agenus.
Mr. Wiinberg joins the board as an independent director with
almost 20 years of senior leadership experience, most recently
serving as Chief Executive Officer of H. Lundbeck A/S, a global
pharmaceutical company developing and marketing treatments for
psychiatric and neurological disorders. He previously served on the
boards of several healthcare industry associations and held
multiple executive roles at Wyeth, one of the world’s largest
research-driven pharmaceutical companies that was acquired by
Pfizer in 2009. He served as President of Wyeth Europe, Africa and
Middle East; President of Consumer Healthcare; Managing Director of
Wyeth UK, and in various commercial positions. Mr. Wiinberg
currently serves on the boards of UCB SA, a global
biopharmaceutical company based in Belgium, Avillion LLP
(Chairman), a London-based drug development company, Hansa Medical
AB (Chairman), a Swedish biopharmaceutical company, Alfa Laval AB,
a Swedish industrial company, and Nestle Health Science.
“Agenus’ long pedigree in immunology and cancer along with its
extensive and diverse pipeline and platform technologies has the
potential to transform patient care and outcomes,” Mr. Wiinberg
said. “I look forward to providing my knowledge and support to help
the Company and its outstanding team reach its strategic objectives
at this critical stage of growth.”
About Agenus
Agenus is an immuno-oncology company focused on the discovery
and development of revolutionary new treatments that engage the
body’s immune system to benefit patients suffering from cancer. By
combining multiple powerful platforms, Agenus has established a
highly integrated approach to target identification and validation,
and for the discovery, development and manufacturing of monoclonal
antibodies. The Company’s broad portfolio of novel checkpoint and
other monoclonal antibodies, vaccines and adjuvants, work in
combination to provide the opportunity to create best-in-class
therapeutic regimens. Agenus’ heat shock protein-based vaccine,
Prophage™, has successfully completed Phase 2 trials in
newly-diagnosed glioblastoma. The Company has formed collaborations
with Merck and Incyte to discover and develop multiple antibodies.
For more information, please visit www.agenusbio.com; information
that may be important to investors will be routinely posted on our
website.
Forward-Looking Statements
This press release contains forward-looking statements that are
made pursuant to the safe harbor provisions of the federal
securities laws, including statements regarding plans for clinical
development, partnership activities and potential commercialization
of any product candidates. These forward-looking statements are
subject to risks and uncertainties that could cause actual results
to differ materially. These risks and uncertainties include, among
others, the factors described under the Risk Factors section of our
most recent Quarterly Report on Form 10-Q or annual report on Form
10-K filed with the Securities and Exchange Commission. Agenus
cautions investors not to place considerable reliance on the
forward-looking statements contained in this release. These
statements speak only as of the date of this press release, and
Agenus undertakes no obligation to update or revise the statements,
other than to the extent required by law. All forward-looking
statements are expressly qualified in their entirety by this
cautionary statement.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160519005114/en/
AgenusAgenus Inc.Michelle Linn,
774-696-3803michelle.linn@agenusbio.comorMedia:BMC
CommunicationsBrad Miles,
646-513-3125bmiles@bmccommunications.com
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024